These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12086567)

  • 1. Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Lu ML; Shen WW
    Ann Pharmacother; 2002; 36(7-8):1292; author reply 1292-3. PubMed ID: 12086567
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of antipsychotic drugs.
    Meibach RC
    Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract]   [Full Text] [Related]  

  • 4. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study.
    Robinson KA
    Clin Ther; 2000 Nov; 22(11):1375-6. PubMed ID: 11117662
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Abraham D; Kissling W
    Schizophr Res; 1999 Jan; 35(1):51-68. PubMed ID: 9988841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
    Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
    Inada T; Beasley CM; Tanaka Y; Walker DJ
    Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
    Inada T; Yagi G; Miura S
    Schizophr Res; 2002 Oct; 57(2-3):227-38. PubMed ID: 12223254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events related to olanzapine.
    Conley RR; Meltzer HY
    J Clin Psychiatry; 2000; 61 Suppl 8():26-9; discussion 30. PubMed ID: 10811240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol.
    Lee MD; Clifton PG
    Pharmacol Biochem Behav; 2002; 71(1-2):147-54. PubMed ID: 11812517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
    Windhaber J; Urbanits S; Grisold W
    Neurology; 2000 Apr; 54(7):1543-4. PubMed ID: 10751282
    [No Abstract]   [Full Text] [Related]  

  • 18. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine and haloperidol: potential for neutropenia?
    Abdullah N; Voronovitch L; Taylor S; Lippmann S
    Psychosomatics; 2003; 44(1):83-4. PubMed ID: 12515844
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.